Agenus shares surge 20.06% intraday after Q4 earnings and revenue beat estimates, losses narrow 84%, and B.Riley reaffirms $8 price target.

Agenus surged 20.06% intraday following a Q4 earnings report that exceeded expectations, with a $0.56 per share profit (vs. Zacks’ loss estimate of $1.27/share) and 27.5% year-over-year revenue growth to $34.2 million. The stock also benefited from B.Riley reaffirming a $8 Buy rating, reflecting confidence in Agenus’ narrowed losses (84.5% improvement to $0.30/share) and strategic advancements, including a $91 million Zydus collaboration to boost U.S. manufacturing for its BotVal immunotherapy. The CEO highlighted progress in Phase 3 trials and early revenue from global access programs, reinforcing optimism about regulatory milestones and clinical data. The sharp intraday rally aligns with the positive earnings surprise, reduced losses, and analyst upgrade, signaling renewed investor confidence in the company’s operational efficiency and growth trajectory.